Vivoryon Therapeutics N.V.
VVY.AS · AMS
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €0 | -€4 | €0 | €11 |
| % Growth | 100% | – | -100% | – |
| Cost of Goods Sold | €0 | -€1 | €0 | €2 |
| Gross Profit | -€0 | -€3 | -€0 | €9 |
| % Margin | – | 85.5% | – | 83.9% |
| R&D Expenses | €14 | €18 | €20 | €17 |
| G&A Expenses | €7 | €3 | €9 | €0 |
| SG&A Expenses | €7 | €3 | €9 | €4 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €4 |
| Other Operating Expenses | €0 | €5 | €0 | €0 |
| Operating Expenses | €21 | €26 | €29 | €22 |
| Operating Income | -€21 | -€29 | -€29 | -€13 |
| % Margin | – | 796.6% | – | -119% |
| Other Income/Exp. Net | €0 | €0 | €1 | €1 |
| Pre-Tax Income | -€21 | -€29 | -€28 | -€12 |
| Tax Expense | €0 | -€0 | -€0 | €0 |
| Net Income | -€21 | -€28 | -€28 | -€13 |
| % Margin | – | 782.9% | – | -117.6% |
| EPS | -0.79 | -1.12 | -1.28 | -0.63 |
| % Growth | 29.5% | 12.5% | -103.2% | – |
| EPS Diluted | -0.79 | -1.12 | -1.28 | -0.63 |
| Weighted Avg Shares Out | 26 | 25 | 22 | 20 |
| Weighted Avg Shares Out Dil | 26 | 25 | 22 | 20 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | -€20 | -€28 | -€28 | -€12 |
| % Margin | – | 783.2% | – | -111.8% |